Business ❯ Finance ❯ Mergers and Acquisitions

Pharmaceuticals

Obesity Drugs Alkermes and Avadel Pharmaceuticals Biotech Companies Torrent Pharmaceuticals Eli Lilly Oncology Supernus Pharmaceuticals Immunology Rare Diseases Biontech-Curevac Acquisition Company Acquisitions COPD Treatments Pfizer Inc. Gene Therapy Cardiovascular Drugs Anti-obesity Drugs Ophthalmology Antitrust Issues Pfizer Industry Trends Market Impact JB Chemicals Regulatory Approval Legal Disputes Bidding Wars Evoke Pharma, Inc. Novo Nordisk Metsera Biotech Lundbeck Cidara Therapeutics Weight Loss Drugs Sanofi Acquisition of Amicus Therapeutics Novo Holdings Acquisition Neurological Disorders Walgreens Business Sale Biotechnology 23andMe

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

GSK moves to fortify its immunology pipeline with a mid‑stage anti‑IgE drug that could shift food‑allergy care.

Lundbeck Challenges Alkermes With Up to $23-Per-Share Offer for Avadel

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Metsera Backs Pfizer’s $10 Billion Deal, Citing Regulatory Risks in Novo Bid

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Lilly to Buy Adverum in Gene‑Therapy Deal Worth Up to $12.47 a Share

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

Pfizer to Buy Metsera for $4.9 Billion Upfront in Return to Obesity Drugs

Novartis to Acquire Tourmaline Bio for $1.4 Billion to Bolster Heart-Drug Pipeline

Merck to Acquire Verona Pharma in $10 Billion Deal for Ohtuvayre COPD Therapy

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline